100 related articles for article (PubMed ID: 17957368)
1. Tumor, tissue, and plasma pharmacokinetic studies and antitumor response studies of docetaxel in combination with 9-nitrocamptothecin in mice bearing SKOV-3 human ovarian xenografts.
Zamboni WC; Strychor S; Joseph E; Parise RA; Egorin MJ; Eiseman JL
Cancer Chemother Pharmacol; 2008 Aug; 62(3):417-26. PubMed ID: 17957368
[TBL] [Abstract][Full Text] [Related]
2. Clinical and pharmacokinetic study evaluating the effect of food on the disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in patients with solid tumors.
Zamboni WC; Goel S; Iqbal T; Parise RA; Strychor S; Repinski TV; Egorin MJ; Mani S
Cancer Chemother Pharmacol; 2006 May; 57(5):631-9. PubMed ID: 16205924
[TBL] [Abstract][Full Text] [Related]
3. Relationship between plasma exposure of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite and antitumor response in mice bearing human colon carcinoma xenografts.
Zamboni WC; Jung LL; Egorin MJ; Hamburger DR; Joseph E; Jin R; Strychor S; Ramanathan RK; Eiseman JL
Clin Cancer Res; 2005 Jul; 11(13):4867-74. PubMed ID: 16000585
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic studies of 9-nitrocamptothecin on intermittent and continuous schedules of administration in patients with solid tumors.
Jung LL; Ramanathan RK; Egorin MJ; Jin R; Belani CP; Potter DM; Strychor S; Trump DL; Walko C; Fakih M; Zamboni WC
Cancer Chemother Pharmacol; 2004 Dec; 54(6):487-96. PubMed ID: 15322760
[TBL] [Abstract][Full Text] [Related]
5. Phase I and pharmacologic study of intermittently administered 9-nitrocamptothecin in patients with advanced solid tumors.
Zamboni WC; Jung LL; Egorin MJ; Potter DM; Friedland DM; Belani CP; Agarwala SS; Wong MM; Fakih M; Trump DL; Jin R; Strychor S; Vozniak M; Troetschel M; Ramanathan RK
Clin Cancer Res; 2004 Aug; 10(15):5058-64. PubMed ID: 15297407
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of the in vivo and in vitro conversion of 9-nitro-20(S)-camptothecin to 9-amino-20(S)-camptothecin in humans, dogs, and mice.
Hinz HR; Harris NJ; Natelson EA; Giovanella BC
Cancer Res; 1994 Jun; 54(12):3096-100. PubMed ID: 8205523
[TBL] [Abstract][Full Text] [Related]
7. Antitumor mechanisms of systemically administered epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck.
Thomas SM; Ogagan MJ; Freilino ML; Strychor S; Walsh DR; Gooding WE; Grandis JR; Zamboni WC
Mol Pharmacol; 2008 Mar; 73(3):627-38. PubMed ID: 18025070
[TBL] [Abstract][Full Text] [Related]
8. 9-Nitrocamptothecin liposome aerosol treatment of melanoma and osteosarcoma lung metastases in mice.
Koshkina NV; Kleinerman ES; Waidrep C; Jia SF; Worth LL; Gilbert BE; Knight V
Clin Cancer Res; 2000 Jul; 6(7):2876-80. PubMed ID: 10914737
[TBL] [Abstract][Full Text] [Related]
9. Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes.
Zamboni WC; Ramanathan RK; McLeod HL; Mani S; Potter DM; Strychor S; Maruca LJ; King CR; Jung LL; Parise RA; Egorin MJ; Davis TA; Marsh S
Invest New Drugs; 2006 Sep; 24(5):393-401. PubMed ID: 16505951
[TBL] [Abstract][Full Text] [Related]
10. Plasma, tumor, and tissue disposition of STEALTH liposomal CKD-602 (S-CKD602) and nonliposomal CKD-602 in mice bearing A375 human melanoma xenografts.
Zamboni WC; Strychor S; Joseph E; Walsh DR; Zamboni BA; Parise RA; Tonda ME; Yu NY; Engbers C; Eiseman JL
Clin Cancer Res; 2007 Dec; 13(23):7217-23. PubMed ID: 18056203
[TBL] [Abstract][Full Text] [Related]
11. Tumor disposition of pegylated liposomal CKD-602 and the reticuloendothelial system in preclinical tumor models.
Zamboni WC; Eiseman JL; Strychor S; Rice PM; Joseph E; Zamboni BA; Donnelly MK; Shurer J; Parise RA; Tonda ME; Yu NY; Basse PH
J Liposome Res; 2011 Mar; 21(1):70-80. PubMed ID: 20528623
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice.
Schluep T; Cheng J; Khin KT; Davis ME
Cancer Chemother Pharmacol; 2006 May; 57(5):654-62. PubMed ID: 16133526
[TBL] [Abstract][Full Text] [Related]
13. An injectable depot system for sustained intraperitoneal chemotherapy of ovarian cancer results in favorable drug distribution at the whole body, peritoneal and intratumoral levels.
Zahedi P; Stewart J; De Souza R; Piquette-Miller M; Allen C
J Control Release; 2012 Mar; 158(3):379-85. PubMed ID: 22154933
[TBL] [Abstract][Full Text] [Related]
14. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
15. Anticancer activity of stabilized palifosfamide in vivo: schedule effects, oral bioavailability, and enhanced activity with docetaxel and doxorubicin.
Jones B; Komarnitsky P; Miller GT; Amedio J; Wallner BP
Anticancer Drugs; 2012 Feb; 23(2):173-84. PubMed ID: 22027537
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic advantage of intraperitoneal injection of docetaxel in the treatment for peritoneal dissemination of cancer in mice.
Shimada T; Nomura M; Yokogawa K; Endo Y; Sasaki T; Miyamoto K; Yonemura Y
J Pharm Pharmacol; 2005 Feb; 57(2):177-81. PubMed ID: 15720780
[TBL] [Abstract][Full Text] [Related]
17. Growth inhibition of established B16-F10 lung metastases by sequential aerosol delivery of p53 gene and 9-nitrocamptothecin.
Gautam A; Waldrep JC; Densmore CL; Koshkina N; Melton S; Roberts L; Gilbert B; Knight V
Gene Ther; 2002 Mar; 9(5):353-7. PubMed ID: 11938455
[TBL] [Abstract][Full Text] [Related]
18. The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically.
Garofalo A; Naumova E; Manenti L; Ghilardi C; Ghisleni G; Caniatti M; Colombo T; Cherrington JM; Scanziani E; Nicoletti MI; Giavazzi R
Clin Cancer Res; 2003 Aug; 9(9):3476-85. PubMed ID: 12960140
[TBL] [Abstract][Full Text] [Related]
19. 9-Nitrocamptothecin is an effective drug for the treatment of human lung tumors: comparison of in vitro and in vivo studies.
Han Z; Wyche JH; Sands H; Pantazis P
Anticancer Res; 2001; 21(3B):1823-7. PubMed ID: 11497265
[TBL] [Abstract][Full Text] [Related]
20. Self-microemulsifying drug delivery system (SMEDDS) improves anticancer effect of oral 9-nitrocamptothecin on human cancer xenografts in nude mice.
Lu JL; Wang JC; Zhao SX; Liu XY; Zhao H; Zhang X; Zhou SF; Zhang Q
Eur J Pharm Biopharm; 2008 Aug; 69(3):899-907. PubMed ID: 18434109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
